CSIMarket Company Name, Ticker, Competitors, else..


Emmaus Life Sciences Inc   (EMMAW)
Other Ticker:  
 

Emmaus Life Sciences Inc

EMMAW's Fundamental analysis



Looking into Emmaus Life Sciences Inc growth rates, revenue grew by 9.17 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 1721

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.75 %

Emmaus Life Sciences Inc 's net income grew by 2626.87 % in III. Quarter 2024 year on year, above company average,

• More on EMMAW's Growth


Emmaus Life Sciences Inc
realized a net loss in trailing twelve months.

Emmaus Life Sciences Inc realized cash reduction of $ -0 per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.45.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.23.


• More on EMMAW's Valuation
 
 Total Debt (Millions $) 16
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 573,886
 Net Income/Employee (TTM) $ -99,886
 Receivable Turnover (TTM) 4.45
 Tangible Book Value (Per Share $) -0.33

Emmaus Life Sciences Inc
realized net loss in trailing twelve months.

Emmaus Life Sciences Inc realized cash outflow of $ -0per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.45.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.23.


• More on EMMAW's Valuation

•  Market Capitalization (Millions $) 9
•  Shares Outstanding (Millions) 163
•  Employees 35
•  Revenues (TTM) (Millions $) 20
•  Net Income (TTM) (Millions $) -4
•  Cash Flow (TTM) (Millions $) 0
•  Capital Exp. (TTM) (Millions $) -
•  Total Debt (Millions $) 16
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 573,886
•  Net Income/Employee(TTM) $ -99,886
•  Receivable Turnover Ratio (TTM) 4.45
•  Tangible Book Value (Per Share $) -0.33

•  Market Capitalization (Millions $) 9
•  Shares Outstanding (Millions) 163
•  Employees 35
•  Revenues (TTM) (Millions $) 20
•  Net Income (TTM) (Millions $) -4
•  Cash Flow (TTM) (Millions $) 0
•  Capital Exp. (TTM) (Millions $) -


    EMMAW's Profitability Comparisons
Emmaus Life Sciences Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 14.99 % from 10.82 % in II. Quarter.

Emmaus Life Sciences Inc net profit margin of 33.35 % is currently ranking no. 17 in Major Pharmaceutical Preparations industry, ranking no. 30 in Healthcare sector and number 290 in S&P 500.


Profitability by Segment
Total 33.35 %



  Ratio
•   Capital Ratio (MRQ) 0.14
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 0.72
•  Inventory Turnover Ratio (TTM) 0.64



Emmaus Life Sciences Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 14.99 % from 10.82 % in II. Quarter.

Emmaus Life Sciences Inc net profit margin of 33.35 % is currently ranking no. 17 in Major Pharmaceutical Preparations industry, ranking no. 30 in Healthcare sector and number 290 in S&P 500.

• More on EMMAW's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com